NCT Number: NCT05081193
Phase: Phase 2
Trial Summary: Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone ma – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acronym:
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives